Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
Avidity to report FSHD data from FORTITUDE ™ trial this quarter and DMD data from EXPLORE44 ™ trial in 2H24 Presented positive long-term del-desiran data from MARINA-OLE ™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vHOT as primary, agreed for phase 3 HARBOR trial Cash position of $915 million at the end of Q124 following successful private placement SAN DIEGO May 9, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024 , and highlighted recent corporate progress. "As we move forward with the planned initiation of our global Phase 3 HARBOR™ study for del-desiran this quarter, we continue to work diligently to improve people's lives by advancing our AOC platform," sa
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsPR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.MarketBeat
- Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.MarketBeat
- Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsPR Newswire
RNA
Earnings
- 5/9/24 - Beat
RNA
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 3
- RNA's page on the SEC website